MedTrace Logo

Can Cholesterol Lowering Drugs Influence Circulating Omega-3 Fatty Acid Levels

NCT00955227 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2016-05-12

No results posted yet for this study

Summary

The objective of this study is to determine if the administration of a cholesterol lowering drug like ezetimibe will reduce circulating omega-3 fatty acid (ALA) levels in patients with heart disease and hypercholesterolemia.

The investigators hypothesize that their data will discover that patients receiving ezetimibe require additional dietary supplementation with omega-3 supplements to insure that these beneficial fatty acids are available to these patients.

Conditions

Interventions

DIETARY_SUPPLEMENT

Flax seed oil (ALA)

2 capsules each containing 500mg of ALA will be taken once per day for 6 weeks

DRUG

Ezetimibe

In total, 30 patients will receive ezetimibe as a drug intervention. The dosage is 10mg pod for 6 weeks

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • University of Manitoba

    lead OTHER

Principal Investigators

  • Grant N Pierce, PhD · St. Boniface Hospital

  • Davinder Jassal · St. Boniface Hospital

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2011-05-31
Completion
2015-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00955227 on ClinicalTrials.gov